Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
Business Insider7d
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...
Yahoo Finance1mon
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
The alliance expands upon existing collaborations between MD Anderson researchers and Myriad, including ongoing studies in breast cancer and renal cell carcinoma. Myriad Genetics is a leading ...
Nasdaq14d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Typically, prenatal cell-free DNA (pcfDNA ... Chief Scientific Officer at Myriad Genetics. “We are improving the timeline for patients to understand their risk assessment of chromosomal ...
The Bakersfield Californian14d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...